SII CEO Adar Poonawalla said that the company will start selling the Covishield to the Indian government and GAVI (Global Alliance for Vaccines and Immunisation) nations in the first stage, followed by the private market

Pfizer's statement has come after several reports have surfaced which indicated that the government wouldn't be procuring the Pfizer-BioNTech vaccine because of its high cost and the extreme cold chain requirement of -70 degree Celsius

 India readies for 60 crore doses of Covid-19 vaccines to be administered to the most vulnerable people through conventional cold chain systems, says top government expert

Albert Bourla, the CEO of Pfizer, said the company will have tiered pricing for the middle-income countries (including, India) and will give the vaccine free in Africa

India Stock Market Highlights Today: Intraday, both indices touched all time highs today, with Sensex hitting 46,164 and Nifty touching 13,548.

Pfizer's clarification comes as experts believe that storing the vaccine in minus 70 degree Celsius would be a big hurdle

After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon

Indian drug regulator may provide an emergency approval to AstraZeneca's COVID-19 vaccine by end-December or early January 21, says Nomura

Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public

Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh

Mankind has been promoting DrOnA Health among doctors as a service to help them. Over 10,000 doctors are now using the facility. Another special feature of the app is that it allows doctors to have complete ownership of data.

Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical

Though margins remain healthy, pricing pressures for the US base generics business, lack of limited competition products and manufacturing quality issues will continue to trouble them, said ICRA

Coronavirus drug: Jenburkt Pharmaceuticals is the latest company to roll out Favipiravir for Rs 39 per tablet - its cheapest pricing yet

Coronavirus (Covid-19) Vaccine News Latest Updates:  The study showed that curcumin can prevent Transmissible gastroenteritis virus (TGEV)- an alpha-group coronavirus that infects pigs, from infecting cells. The higher doses of curcumin were also found to kill virus particles

Coronavirus treatment: Patients who were administered Glenmark's FabiFlu saw 40 per cent faster achievement of clinical cure

Glenmark says compared to other therapies approved for emergency use in COVID-19 in India, FabiFlu is much more economical and an effective treatment option; DCGI had earlier asked it to clarify on allegation that the drug was unaffordable due to its high pricing

\"Compared to other therapies approved for emergency use in COVID-19, FabiFlu is much more economical and an effective treatment option,\" the company said in a statement to the exchanges

For months before studies like these, learning what helps or harms has been undermined by \"desperation science\" as doctors and patients tried therapies on their own or through a host of studies not strong enough to give clear answers

The drug major, which has presence in around 150 countries, caters to various various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others